PHARMACOECONOMIC STUDY OF THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ADULT PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN RUSSIAN FEDERATION

Aim to perform the analysis of different agonists of thrombopoietin receptors - romiplostim and eltrombopag in adult patients with chronic idiopathic thrombocytopenic purpura (ITP) in Russia.
Methodology. There has been developed model of medical care patients with ITP based on the research hypothesis suggesting the possible low level of compliance in certain categories of patients for long-term independent daily intake of the drug eltrombopag (50 mg tablets). To evaluate the clinical practice for ITP patients in Russia the interview of experts was performed. Direct medical costs were calculated per 1 patient.
Results. Total costs of the treatment per ITP patient within the 1 year period were 3,895,692 rubles with romiplostim and 1,788,537 rubles with eltrombopag. However, taking into account a possible low level of compliance of certain categories of patients in clinical practice in Russia and therefore the probable decline of the efficacy of therapy the cost-effectiveness ratio for romiplostim amounted to 4,693,605 rubles/1 case of the effective treatment if compared with 6,387,631 rubles/1 case of the effective treatment for eltrombopag. The difference amounted to 1,694,026 rubles in favor of the drug romiplostim.
Conclusion The use of romiplostim in the treatment of adult ITP patients was both effective and economically justified as treatment option in real practice in patients with low compliance in Russia.

1. Cooper K.L., Fitzgerald P., Dillingham K., Helme K., Akehurst R. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. Int. J. Technol. Assess. Health Care. 2012; 28(3): 249–58. doi: 10.1017/S0266462312000414.

2. Cooper K.L., Matcham J., Helme K., Akehurst R. Update on romiplostim and eltrombopag indirect comparison. Int. J. Technol. Assess. Health Care. 2014; 30(1): 129–30. doi: 10.1017/S0266462313000767.

3. Kuter D.J., Bussel J.B., Lyons R.M., Pullarkat V., Gernsheimer T.B., Senecal F.M., et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet. 2008; 371(9610): 395–403. doi: 10.1016/S0140-6736(08)60203-2.

4. Cheng G., Saleh M.H., Marcher C., Vasey S., Mayer B., Aivado M., et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377(9763): 393–402. doi: 10.1016/S0140-6736(10)60959-2.

5. Adherence to long-term therapies: Evidence for action. WHO. 2003. Available at http://www.who.int/chp/knowledge/publications/adherence_report/en/ (accessed 09 Nov 2016)

6. Official instructions for use of the drug Revoleyd®. State Register of Medicinal Products. Available at http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=47fe644f-aba4-433d-91f3-7bcf620237cf&t= (accessed 09 Nov 2016). (in Russian)

7. Bussel J.B., Cheng G., Saleh M.N., Psaila B., Kovaleva L., Meddeb B., et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med. 2007; 357(22): 2237–47.

8. Clinical guidelines for the diagnosis and treatment of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. The National Society of Hematology. Hematology and Transfusiology. Russian journal (Gematologiya i Transfusiologiya). 2015; 60(1): 44–56. Available at http://www.minzdravrb.ru/minzdrav/docs/itp.pdf (accessed 09 Nov 2016)

9. Gernsheimer T.B., George J.N., Aledort L.M., Tarantino M.D., Sunkara U., Matthew Guo D., Nichol J.L. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J. Thromb Haemost. 2010; 8(6): 1372–82. doi: 10.1111/j.1538-7836.2010.03830.x.

10. Guidelines for health care payment methods at the expense of the compulsory health insurance system. Federal Compulsory Medical Insurance Fund. 2015. Available at http://www.ffoms.ru/news/ffoms/o-metodicheskikh-rekomendatsiyakh-po-sposobam-oplatymeditsinskoy-pomoshchi-za-schet-sredstv-obyazat/# (accessed 09 Nov 2016)